Birth rates among male cancer survivors and mortality rates among their offspring: a population-based study from Sweden by Tang, S-W et al.
RESEARCH ARTICLE Open Access
Birth rates among male cancer survivors
and mortality rates among their offspring: a
population-based study from Sweden
Siau-Wei Tang1, Jenny Liu1,2, Lester Juay2, Kamila Czene3, Hui Miao2, Agus Salim4, Helena M Verkooijen2,5
and Mikael Hartman1,2,3*
Abstract
Background: With improvements in treatment of cancer, more men of fertile age are survivors of cancer. This
study evaluates trends in birth rates among male cancer survivors and mortality rates of their offspring.
Methods: From the Swedish Multi-generation Register and Cancer Register, we identified 84,752 men ≤70 years
with a history of cancer, for which we calculated relative birth rates as compared to the background
population(Standardized Birth Ratios, SBRs). We also identified 126,696 offspring of men who had cancer, and
compared their risks of death to the background population(Standardized Mortality Ratio, SMRs). Independent
factors associated with reduced birth rates and mortality rates were estimated with Poisson modelling.
Results: Men with a history of cancer were 23 % less likely to father a child compared to the background
population(SBR 0.77, 95 % Confidence Interval[CI] 0.75–0.79). Nulliparous men were significantly more likely to
father a child after diagnosis (SBR 0.81, 95 % CI 0.79–0.83) compared to parous men (SBR 0.68, 95 % CI 0.66–0.74).
Cancer site(prostate), onset of cancer during childhood or adolescence, parity status at diagnosis(parous), current
age(>40 years) and a recent diagnosis were significant and independent predictors of a reduced probability of
fathering a child after diagnosis.
Of the 126,696 children born to men who have had a diagnosis of cancer, 2604(2.06 %) died during follow up.
The overall mortality rate was similar to the background population(SMR of 1.00, 95 %CI 0.96–1.04) and was not
affected by the timing of their birth in relation to father’s cancer diagnosis.
Conclusion: Male cancer survivors are less likely to father a child compared to the background population. This is
influenced by cancer site, age of onset and parity status at diagnosis. However, their offspring are not at an
increased risk of death.
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Background
With early diagnosis, advancing treatment and improved
survival rates of childhood and early adult cancer, an
increasing proportion of boys and young men with can-
cer are more likely to survive their disease to reach
reproductive ages [1]. This has led to an increased inter-
est in the quality of life and reproductive potential of
this group of cancer survivors. Some forms of cancer
may directly affect fertility through adverse effects on
the physiology of the male reproductive organs or
endocrine glands; eg. Testicular cancer. Loco-regional or
systemic treatment procedures such as pelvic surgery,
radiotherapy or chemotherapy may induce temporary or
permanent infertility in men through the disruption of
ejaculatory functions or cytotoxic effects on spermato-
genesis [2, 3].
The advances in medicine have had a contrasting
effect on fertility in cancer survivors. On one hand,
newer chemotherapeutic treatment regimes (eg. the use
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of procarbazine with alkylating agents in Hodgkin’s
disease) or gonadal/whole body irradiation has a higher
chance of sterilising patients [4, 5]. However, the develop-
ment of fertility preservation techniques in men, such as
semen cryopreservation and testicular sperm extraction;
in combination with artificial reproductive techniques of
in-vitro fertilisation (IVF) or intra-cystoplasmic sperm
injection (ICSI) have offered men a possibility of parent-
hood after cancer [4, 5].
Psychologically, the diagnosis of cancer may increase
the value placed on family and the importance of parent-
hood for the cancer survivors [6, 7]. However, this may
be contradicted with his own uncertainties of his cancer
prognosis, a perceived risk of passing the cancer suscep-
tibility on to his offspring, treatment-related harm to the
offspring and other social and cultural influences. Stud-
ies have shown that cancer patients are less likely to
father a pregnancy after their disease as compared to
their siblings [8, 9].
Various studies have not shown any adverse pregnancy
outcomes for the partners of male childhood cancer
survivors [10, 11]. However, few studies have been
conducted in adult male cancer survivors. It is unclear if
the exposure to (the effects of ) diagnostic investigations,
radiation therapy, and systemic treatment before and
around the time of birth may have any adverse effects
on spermatogenesis and the subsequent wellbeing of the
offspring.
In this study, we aim to evaluate trends in birth rates
among Swedish male cancer survivors by age and over
time, as well as the factors which independently affect
their probability of fatherhood after diagnosis. We also
aim to assess the mortality risks in offspring of these
men with a history of cancer in relation to timing of
birth and cancer site.
Methods
Study design
We used the Multi-Generation Register(MGR) [12], the
Swedish Cancer Register [13], the Cause of Death
Register, and the Migration Register for this study. The
unique national registration numbers accorded for each
Swedish individual was used as a linkage between the
registries and the Censuses of 1960, 1970, 1980, and
1990, to obtain further information on the socioeco-
nomic status of each Swedish citizen. Information was
extracted on cancer site as defined by the International
Classification of Diseases, Revision 7 code (ICD7) [14].
Socioeconomic status was estimated based on informa-
tion about the highest level of employment in the house-
hold given in the Censuses and was categorized into five
groups; blue collar workers, white collar workers, self-
employed workers, farmers and unclassified. In total, this
database contains more than 11 million individuals,
belonging to around three million families and included
more than a million individuals with cancer diagnosed
between 1958 and 2001 [12]. The study design was ap-
proved by the Regional Ethics Review Board at Karolinska
Institutet, Sweden whereby the need for individual consent
from the participants was deemed unnecessary.
Birth rates among male cancer survivors
Our study base consisted of all men aged 16 to 70 years,
born after 1931, who were alive between 1961 and 2002
and present in the Multi-Generation Register. The part-
ners or spouse of these men were identified and tracked
for up to 10 months after the men have passed away/
emigrated to ensure all information of their offspring
were included. For each man, we ascertained the num-
ber and dates of live child births (multiple pregnancies
were counted as one event/birth), with their partners or
spouse, socioeconomic status, date of cancer diagnosis
(if present) and followed them until death, emigration or
end of follow up (31st December 2002), whichever came
first. End of follow-up was chosen at 31st December
2002, where records of cancer, death, migration and so-
cioeconomic status were all available on the numerous
registers. For men diagnosed with cancer, we calculated
the proportion and relative probability of fathering an
offspring after diagnosis.
We included all births >1 year after diagnosis, as most
patients would have received complete information on
treatment plan and prognosis by then, with the decision
to have an offspring considered with the knowledge of
the cancer diagnosis. For the background population,
cancer-free men in the background population were
matched to the male cancer survivors according to
attained age and year of birth, and the number of live
child births of the spouse of these men in the back-
ground population was then ascertained. Using the
above criteria, there were 4,032,096 Swedish men in the
Swedish MGR, where 87,302 men had a history of
cancer (Fig. 1). Over the study period, 2550 participants
(0.03 %) were lost to follow-up and 883,548 (22.4 %)
were excluded from the study population as they were
out of the observed age range of 16 to 70 years old or
had emigrated. Missing data is equally likely in both the
male cancer survivors and the background population
which is why we chose to use standardized birth ratio to
handle the non-differential bias.
Mortality rate among offspring of male cancer survivors
For the offspring of fathers with a history of cancer we
extracted information on date of birth, date of death and
cause of death. Each individual offspring in multiple
pregnancies was counted separately. 126, 696 offspring
of 64,451 men in the study population with cancer and
whose partners gave birth during the observation period
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were identified and followed up for a median of
32.3 years (range 0–42.9 years). Causes of death were
regrouped as congenital anomalies (ICD7: 750–759),
perinatal conditions (ICD7: 760–776),neoplasms (ICD7:
140–239) and others (i.e. all remaining causes com-
bined). Offspring were followed from birth until death,
emigration, or end of follow-up (31st December 2003),
whichever came first.
In order to investigate the association between timing of
birth in relation to the father’s cancer diagnosis, we cate-
gorized offspring into three groups: offspring born more
than 1 year before their father’s cancer diagnosis (Group
1), offspring born between 1 year before and 1 year after
their father’s diagnosis (Group 2), and offspring born more
than 1 year after their father’s cancer diagnosis (Group 3).
The rationale behind these (arbitrary) cut off levels was
that children born more than 1 year before their father’s
diagnosis were not exposed to the cancer process itself,
nor to the diagnostic investigations, or treatment.
Children born around their father’s diagnosis may have
been conceived with sperm that were directly exposed to
the cancer process itself, the diagnostic investigations
(involving ionizing radiation), and the cancer treatment.
Finally, children born more than 1 year after their father’s
diagnosis have not been directly exposed to cancer
treatment, but mutagenic effects of cancer treatment or
damage to the reproductive organs in the father may still
affect their outcome.
Statistical analysis
Relative birth rates were expressed as a Standardized
Birth Ratios (SBRs), i.e. the ratio of observed births in
our study group to the expected number of births, based
on birth rates in the background population. Person-
Fig. 1 Flowchart of the Swedish male population in the Multi-Generation Register (MGR) aged 16 to 70 years, born after 1931, who were alive
in 1961
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years at risk of giving birth were calculated from 1 year
after the time of cancer diagnosis or 16th birthday, which-
ever came later; until 10 months after date of death or
emigration, 17th birthday or end of follow up (31st
December 2003), whichever came first. Background birth
rates were derived using birth rates for all men present in
the Multi-Generation Register [12]. The expected number
of births was calculated by multiplying the 5-year age- and
calendar period specific birth rates in the background
population by correspondingly stratified person-years at
risk and summing all the products. We then compared
relative birth rates by age at onset (childhood-below the
age of 13 years-, adolescence−13 to 18 years-and adult-
hood > 18 years), attained age, year and parity status at
diagnosis, cancer site, time since diagnosis, attained year,
and socioeconomic status.
Relative risks of death in offspring were expressed
as Standardized Mortality Ratios(SMRs), i.e. the ratio
of observed to expected number of deaths. Person-
years were calculated as the time from the child’s
birth to death, emigration, or end of follow up
(31stDecember 2003), whichever came first. Background
mortality rates were derived using mortality rates of
3,620,127 offspring of 3,060,345 men present in the
Multi-Generation Register (Fig. 1). The expected number
of deaths was calculated by multiplying the 5-year age and
calendar period specific mortality rates in the background
population by correspondingly stratified person-years at
risk in the cohort and summing all the products. We
calculated overall SMRs by timing of birth in relation
to father’s diagnosis and stratified attained age of the
offspring and cancer site.
A multivariate Poisson regression modelling was per-
formed on data from the study population only, to iden-
tify independent predictors of fatherhood after diagnosis
and the mortality of the offspring of cancer survivors.
The relative risks of fatherhood were expressed as Birth
Rate Ratios (BRRs), which were adjusted for parity status
at diagnosis, cancer site, age and year of diagnosis, time
since diagnosis, calendar period, attained age and socio-
economic status. The BRRs was also used to estimate
whether factors linked with mortality in the offspring
on univariate analysis remained significantly associ-
ated after adjustment for father’s age at childbirth,
mother’s age at childbirth, attained age of child,
calendar year and socioeconomic status. Relative risks
were expressed as Mortality Rate Ratios (MRRs).
Finally, we compared causes of death in offspring of
fathers with cancer to causes of death of children in
the background population. Chi-square and Kruskal-
Wallis tests were used to test for differences in the
distribution of causes of death. Data preparation and
analysis was done with SAS® version 9.2(SAS Institute
Inc., Cary, North Carolina).
Results
The study population included 3,145,998 Swedish men,
of whom 84,752 (2.8 %) were diagnosed with cancer be-
fore age 70 years (Fig. 1). Most of the men (95.7 %) were
diagnosed with cancer in adulthood (19–70 years), with
the commonest site being digestive tract (n = 14,817)
and prostate (n = 11,281) (Table 1). Among the cancer
survivors (group 3), 4973 (5.9 %) men had partners who
gave birth to a total of 7910 births 1 year after their
diagnosis. A higher proportion of men who were diag-
nosed in childhood (19.5 %) and adolescence (22.8 %)
fathered a child after the diagnosis, compared with men
diagnosed in adulthood (5.2 %).
Men diagnosed with cancer were 23 % less likely to have
a child (SBR 0.77, 95 % CI 0.75–0.79) compared to the
background population (Table 2). This remained fairly
consistent over calendar time. Men who were diagnosed in
childhood had a significantly lower birth rate (SBR 0.62, 95
% CI 0.57–0.67) than men diagnosed in adulthood (SBR
0.80, 95 % CI 0.78–0.82) when compared to the back-
ground population. Survivors of skin, thoracic cancer and
head and neck had a birth rate similar to the background
population (SBR 0.98 [0.92–1.04],0.92 [0.74–1.11] and 0.90
[95 % CI 0.80–1.01] respectively); whilst survivors of
prostate, brain and eye, and hematopoietic cancers had a
significant decrease in their birth rates (SBR 0.24 [95 %
CI 0.06–0.54], 0.65 [0.62–0.69] and 0.66 [0.62–0.70]
respectively) compared to the background population.
Men who were parous at the point of cancer diagnosis
had a lower birth rate compared to those who were nul-
liparous (SBR 0.68 [0.66–0.74], 0.81 [95 % CI 0.79–0.83]
respectively). This was particularly pronounced in parous
men who were diagnosed with prostate, thoracic and
haematopoietic cancers (SBR 0.22 [0.04–0.53], 0.48 [0.40–
0.88] and 0.53 [0.46–0.61] respectively) (Table 3). In con-
trast, men who were nulliparous at point of diagnosis of
thoracic, skin, head and neck and digestive cancers had
birth rates which were similar to the background popula-
tion (SBR 1.20 [0.94–1.49], 1.10 [1.01–1.18], 1.06 [0.92–
1.22], 0.97 [0.87–1.08] respectively). However, nulliparous
men who were diagnosed with brain and eye, haematopoi-
etic and reproductive organs cancer still had significantly
lower birth rates compared to the background population
(SBR 0.65 [0.60–0.69], 0.70 [0.65–0.75], 0.75 [0.68–0.77]
respectively).
Multivariate Poisson modelling, adjusting for calendar
period, socioeconomic status, and year of diagnosis
showed that parity status at diagnosis, cancer site, age at
diagnosis, time since diagnosis and attained age were all
independently and significantly associated with the prob-
ability of giving birth after cancer diagnosis (Table 4). Being
parous at diagnosis, a diagnosis of prostate cancer, older
attained age (41–70 years), diagnosis in childhood and ado-
lescence (0–12 and 13–18 years) and a recent diagnosis
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(1–5 and 6–10 years) were significant and independent
predictors of a reduced probability of giving birth after
diagnosis. Men diagnosed in adulthood, increased time
since diagnosis, cancer survivors aged 26–35 and survivors
of thoracic and head and neck cancers were most likely to
father an offspring.
Table 1 Men diagnosed with cancer in Sweden 1960–2002 with information on subsequent birth(s) by age and year of diagnosis,
parity status at diagnosis and cancer site
ICD7 codes Number of men with
previous cancer
Number of men* with births
after cancer diagnosis
Total number of births
after cancer diagnosis
Proportion of men whose
partners gave birth >1 year
after cancer diagnosis
Overall – 84752 4973 7910 5.9 %
Age at diagnosis
0–12
(Childhood)
– 1700 332 610 19.5 %
13–18
(Adolescence)
– 1970 449 891 22.8 %
19–70 (Adult) – 81082 4192 6409 5.2 %
Year of diagnosis
1958 to 1968 – 1854 769 1366 41.5 %
1969 to 1979 – 6289 1265 2271 20.1 %
1980 to 1990 – 18332 1739 2751 9.5 %
1991 to 2001 – 58277 1200 1522 2.1 %
Parity Status at diagnosis
Nulliparous – 22296 3258 5706 14.6 %
Parous – 62456 1715 2204 2.7 %
Cancer site
Digestive 150.0–158.9 14817 350 544 2.4 %
Prostate 177.0–177.9 11281 4 4 0.0 %
Othersa 180.0–181.9; 191.0–191.9;
209.0–209.9
10285 377 611 3.7 %
Bone 196.0–200.9 8764 588 993 6.7 %
Brain & eye 192.0–193.9 7212 715 1188 9.9 %
Hematopoietic 201.0–208.9 7049 575 935 8.2 %
Thoracic 162.0–164.9 6529 55 91 0.8 %
Melanoma
skin
190.0–190.9 6489 679 1032 10.5 %
Reproductive
organs
178.0–179.9 5276 1052 1555 19.9 %
Head & neck 140.0–148.9; 160.0–161.9 3706 167 280 4.5 %
Thyroid 194.0–195.9 3224 408 674 12.7 %
Breast 170.0–170.9 120 3 3 2.5 %
Socio-economic Status
Blue Collar
Workers
– 32294 1884 2923 5.8 %
White Collar
Workers
– 33837 2072 3436 6.1 %
Self-employed – 5723 211 338 3.7 %
Farmers – 1666 81 146 4.9 %
Unclassified – 11232 725 1067 6.5 %
Abbreviations: ICD7 International Classification of Diseases, Revision 7 Codes
*Father’s age at birth of child is 16–70 years
a Including malignant neoplasm of Kidney, Bladder/urinary organs, and other (non-melanoma) malignant neoplasm of the skin
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Between 1961 and 2003, 126,696 children of the total
3,746,823 children were born to men who have had a
diagnosis of cancer at any point in their lives (Fig. 1).
These children were divided into groups based on the
timing of their birth in relation to the diagnosis of their
father’s cancer, where 115,938 children were born more
than a year before their father’s cancer diagnosis, 2707
children born around the time of their father’s diagnosis
and a further 8051 children born more than a year after
their father’s diagnosis (Table 5). There was a total of 2604
deaths in these offspring, where 2500 (2.16 %) of the
deaths occurred in children who were born more than a
year before their father’s cancer diagnosis, 31 (1.15 %)
deaths occurred in children born around the time of their
father’s diagnosis and 73 (0.91 %) deaths occurred in chil-
dren born more than a year after their father’s diagnosis.
Overall, mortality rate of offspring of fathers who have
had a cancer diagnosis was similar to that of the back-
ground population (SMR 1.00, 95 % CI 0.96–1.04). This
remained similar across all three groups of children, re-
gardless of the timing of their birth in relation to their
father’s cancer diagnosis (Table 6). There was no signifi-
cant increase in mortality rate as the child grew older in
all three groups of children. Variation in the father’s
cancer site, age at diagnosis and age at childbirth did not
Table 2 Standardised Birth Ratios (SBRs) of men diagnosed with
cancer in Sweden 1960–2002 with information on subsequent
birth(s) >1 year after cancer diagnosis
Observed Expected SBR
Overall 7910 10252 0.77 (0.75–0.79)
Attained Age
16 to 25 682 999 0.68 (0.63–0.73)
26 to 30 2160 2768 0.78 (0.75–0.81)
31 to 35 2448 3149 0.78 (0.75–0.81)
36 to 40 1572 1929 0.81 (0.78–0.86)
41 to 45 678 866 0.78 (0.72–0.84)
46 to 70 370 541 0.68 (0.62–0.76)
Age at diagnosis
Childhood (0 to 12 years) 610 986 0.62 (0.57–0.67)
Adolescence (13 to 18 years) 891 1235 0.72 (0.67–0.77)
Adulthood (19 to 70 years) 6409 8031 0.80 (0.78–0.82)
Year of diagnosis
1958 to 1968 1366 1708 0.80 (0.76–0.84)
1969 to 1979 2271 2950 0.77 (0.74–0.80)
1980 to 1990 2751 3621 0.76 (0.73–0.79)
1991 to 2001 1522 1973 0.77 (0.73–0.81)
Cancer site
Head & neck 280 312 0.90 (0.80–1.01)
Digestive 544 611 0.89 (0.82–0.97)
Thoracic 91 99 0.92 (0.74–1.11)
Breast 3 6 0.54 (0.10–1.32)
Prostate 4 17 0.24 (0.06–0.54)
Reproductive organs 1555 2201 0.71 (0.67–0.74)
Melanoma skin 1032 1052 0.98 (0.92–1.04)
Brain & eye 1188 1820 0.65 (0.62–0.69)
Thyroid 674 793 0.85 (0.79–0.92)
Bone 993 1211 0.82 (0.77–0.87)
Hematopoietic 935 1421 0.66 (0.62–0.70)
Others 611 711 0.86 (0.79–0.93)
Parity Status at diagnosis
Nulliparous 5706 7032 0.81 (0.79–0.83)
Parous 2204 3221 0.68 (0.66–0.71)
Time since diagnosis
1 to 5 years 3738 4734 0.79 (0.76–0.82)
6 to 10 years 2090 2589 0.81 (0.77–0.84)
11 to 20 years 1558 2156 0.72 (0.69–0.76)
21 to 45 years 524 773 0.68 (0.62–0.74)
Socio-economic Status
Blue Collar Workers 2923 4183 0.70 (0.67–0.72)
White Collar Workers 3436 3869 0.89 (0.86–0.92)
Self-employed 338 399 0.85 (0.76–0.94)
Table 2 Standardised Birth Ratios (SBRs) of men diagnosed with
cancer in Sweden 1960–2002 with information on subsequent
birth(s) >1 year after cancer diagnosis (Continued)
Farmers 146 142 1.03 (0.87–1.20)
Unclassified 1067 1658 0.64 (0.61–0.68)
Bold number units indicate a significant decrease in SBRs
Table 3 Standardized Birth Ratios (SBRs) of men whose partners
gave birth more >1 year after cancer diagnosis by parity status
at cancer diagnosis and cancer site
Cancer site Men whose partners gave birth >1 year after
cancer diagnosis
Nulliparous Parous
Head & neck 1.06 (0.92–1.22) 0.67 (0.54–0.82)
Digestive 0.97 (0.87–1.08) 0.77 (0.67–0.89)
Thoracic 1.20 (0.94–1.49) 0.48 (0.29–0.72)
Breast 0.56 (0.00–2.19) 0.53 (0.05–1.51)
Prostate 0.39 (0.00–1.53) 0.22 (0.04–0.53)
Reproductive organs 0.75 (0.71–0.80) 0.61 (0.56–0.67)
Melanoma skin 1.10 (1.01–1.18) 0.83 (0.74–0.91)
Brain & eye 0.65 (0.60–0.69) 0.68 (0.60–0.77)
Thyroid 0.88 (0.81–0.97) 0.78 (0.68–0.89)
Bone 0.88 (0.82–0.94) 0.65 (0.57–0.74)
Hematopoietic 0.70 (0.65–0.75) 0.53 (0.46–0.61)
Others 0.92 (0.83–1.01) 0.76 (0.67–0.87)
Bold number units indicate a significant decrease in SBRs
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cause a significantly higher mortality rate in the off-
spring compared to the background population. How-
ever, offspring of fathers in Group 3 who were parous at
the start of observation period were shown to have a
higher mortality rate compared to the background popu-
lation (SMR 1.54, 95 % CI 1.06–2.10).
After multivariate analysis with Poisson regression,
adjusting for father’s age at childbirth, mother’s age at
childbirth, father’s socioeconomic factor, attained age of
the child and calendar period, the mortality risk of the
offspring across all three groups of children were similar
to the background population, suggesting that timing of
birth of offspring in relation to the father’s diagnosis of
cancer does not affect the child’s mortality risk (Table 7).
However, increasing father’s age at childbirth and in-
creasing mother’s age at childbirth were shown to be in-
dependent risk factors for increasing mortality risk of
the offspring. Of note, children whose mothers were un-
known were shown to be at an increased mortality risk.
In this study, there was no significant difference between
the causes of death (congenital anomalies, p = 0.172;
perinatal conditions, p = 0.172; neoplasms, p = 0.368)
Table 4 Poisson Regression model of relative likelihood of partners giving birth >1 year after cancer diagnosis of the men,
expressed as Birth Rate Ratios (BRRs)
Number of births Person years Unadj BRR (95 % CI) BRRa (95 % CI)
Parity status at diagnosis
Nulliparous 5706 180421 1.00 1.00
Parous 2204 307707 0.41 (0.39–0.43) 0.74 (0.69–0.79)
Cancer site
Melanoma skin 1032 55946 1.00 1.00
Head & neck 280 23671 1.27 (1.11–1.45) 1.32 (1.15–1.50)
Digestive 544 51622 0.73 (0.66–0.81) 0.99 (0.89–1.10)
Thoracic 91 9954 2.28 (1.84–2.83) 1.83 (1.48–2.27)
Breast 3 647 3.22 (1.04–10.00) 2.89 (0.93–8.98)
Prostate 4 30934 0.04 (0.02–0.12) 0.25 (0.09–0.67)
Reproductive organs 1555 60648 0.96 (0.89–1.04) 0.69 (0.64–0.75)
Brain & eye 1188 54827 0.89 (0.82–0.97) 0.71 (0.65–0.77)
Thyroid 674 35597 1.03 (0.94–1.14) 0.90 (0.81–0.99)
Bone 993 49411 1.05 (0.96–1.15) 0.87 (0.80–0.96)
Hematopoietic 935 47662 0.89 (0.82–0.97) 0.69 (0.63–0.76)
Others 611 67210 0.60 (0.55–0.67) 0.92 (0.83–1.01)
Age at diagnosis
Adulthood (19 to 70 years) 891 24647 1.00 1.00
Adolescence (13 to 18 years) 6409 441720 1.24 (1.16–1.33) 0.76 (0.69–0.83)
Childhood (0 to 12 years) 610 21762 0.90 (0.83–0.98) 0.44 (0.38–0.50)
Time since diagnosis
1 to 5 years 3738 226941 1.00 1.00
6 to 10 years 2090 111500 1.31 (1.24–1.38) 1.10 (1.04–1.17)
11 to 20 years 1558 105367 1.23 (1.16–1.30) 1.23 (1.12–1.34)
21 to 35 years 524 44322 1.63 (1.49–1.79) 2.10 (1.77–2.50)
Attained age
16 to 25 years 682 31079 1.00 1.00
26 to 30 years 2160 26385 3.52 (3.23–3.84) 2.74 (2.48–3.01)
31 to 35 years 2448 35261 3.15 (2.89–3.43) 2.38 (2.15–2.64)
36 to 40 years 1572 43824 1.88 (1.71–2.05) 1.44 (1.28–1.61)
41 to 45 years 678 53092 0.90 (0.81–1.00) 0.69 (0.61–0.80)
46 to 70 years 370 298488 0.31 (0.27–0.35) 0.25 (0.21–0.29)
aAll estimates are adjusted for parity status at diagnosis, cancer site, age and period of diagnosis, time since diagnosis, calendar period, attained age and
socio-economic status. Bold number units indicate a significant difference in BRRs
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Table 5 Timing of childbirth in relation to father’s cancer diagnosis for men born after 1931 and diagnosed with cancer
between 1961–2003
Child born before diagnosisa Child born around diagnosisb Child born after diagnosisc
Offspring Deaths (%) Offspring Deaths (%) Offspring Deaths (%)
Overall 115938 2500 2.16 % 2707 31 1.15 % 8051 73 0.91 %
Attained Age
0–4 yrs old – 1193 – – 17 – – 55 –
5–14 yrs old – 238 – – 4 – – 5 –
15–24 yrs old – 493 – – 5 – – 7 –
25+ yrs old – 576 – – 5 – – 6 –
Father's age at childbirth
16–25 yrs old 25153 696 2.77 % 324 4 1.23 % 668 6 0.90 %
26–30 yrs old 44543 1001 2.25 % 858 14 1.63 % 2175 17 0.78 %
31–35 yrs old 29547 541 1.83 % 732 4 0.55 % 2498 29 1.16 %
36–40 yrs old 11440 195 1.70 % 456 7 1.54 % 1614 12 0.74 %
41–45 yrs old 3690 55 1.49 % 186 2 1.08 % 707 6 0.85 %
46–70 yrs old 1565 12 0.77 % 151 0 0.00 % 389 3 0.77 %
Mother's age at childbirth
12–20 yrs old 11600 342 2.95 % 142 1 0.70 % 216 2 0.93 %
21–25 yrs old 38170 947 2.48 % 613 8 1.31 % 1472 13 0.88 %
26–30 yrs old 40388 777 1.92 % 991 16 1.61 % 2810 22 0.78 %
31–35 yrs old 19301 333 1.73 % 666 3 0.45 % 2412 28 1.16 %
36–40 yrs old 5707 89 1.56 % 249 1 0.40 % 979 7 0.72 %
41–57 yrs old 749 10 1.34 % 44 2 4.55 % 155 1 0.65 %
Unknown 23 2 8.70 % 2 0 0.00 % 7 0 0.00 %
Father's cancer site
Head & neck 5240 130 2.48 % 102 0 0.00 % 284 1 0.35 %
Digestive tract 21949 524 2.39 % 273 3 1.10 % 551 7 1.27 %
Thoracic 9847 268 2.72 % 75 0 0.00 % 94 1 1.06 %
Breast 184 4 2.17 % 2 0 0.00 % 3 0 0.00 %
Prostate 17998 433 2.41 % 14 0 0.00 % 4 0 0.00 %
Reproductive 4620 64 1.39 % 514 4 0.78 % 1599 12 0.75 %
Skin 9115 143 1.57 % 354 5 1.41 % 1045 12 1.15 %
Brain & eye 8047 137 1.70 % 353 1 0.28 % 1199 8 0.67 %
Thyroid 4231 104 2.46 % 159 1 0.63 % 687 8 1.16 %
Bone 11445 210 1.83 % 307 7 2.28 % 1010 7 0.69 %
Hematopoietic 7994 148 1.85 % 359 9 2.51 % 953 10 1.05 %
Others 15268 335 2.19 % 195 1 0.51 % 622 7 1.13 %
Father's parity status at start of observation period
Nulliparous 113903 2444 2.15 % 996 13 1.31 % 5412 39 0.72 %
Parous 2035 56 2.75 % 1711 18 1.05 % 2639 34 1.29 %
aChildren born >1 year prior to father’s cancer diagnosis
bChildren born between 1 year before and 1 year after father’s cancer diagnosis
cChildren born >1 year after father’s cancer diagnosis
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and the timing of the birth of the offspring of fathers
with or without a history of cancer (data not shown).
Discussion
This population based study shows that male cancer sur-
vivors are 23 % less likely to father an offspring com-
pared to the background population. However, there is a
large variation in birth rates depending on cancer site,
age at diagnosis, parity status at diagnosis and time since
diagnosis. Independent predictors for low birth rate fol-
lowing a cancer diagnosis were men who had prostate
cancer, parous at diagnosis, recent diagnosis, diagnosed
in childhood and aged over 40 years.
There are several reasons for the decreased birth
rates among cancer survivors, contributed by the can-
cer itself, the side effects of systemic or locoregional
Table 6 Standardized Mortality Ratios (SMRs) of offspring born by partners of men with a history of cancer by timing of childbirth in
relation to father’s cancer diagnosis
Child born before diagnosisa Child born around diagnosisb Child born after diagnosisc
Overall 0.99 (0.96–1.03) 1.11 (0.75–1.53) 1.15 (0.90–1.43)
Attained Age
0–4 yrs old 0.91 (0.86–0.97) 0.98 (0.57–1.50) 1.30 (0.97–1.66)
5–14 yrs old 1.10 (0.96–1.24) 1.41 (0.37–3.12) 0.77 (0.24–1.59)
15–24 yrs old 1.06 (0.97–1.16) 1.11 (0.35–2.29) 0.66 (0.24–1.29)
25+ yrs old 1.09 (1.00–1.18) 1.57 (0.50–3.25) 1.30 (0.47–2.55)
Father's age at childbirth
16–25 yrs old 1.03 (0.96–1.11) 0.85 (0.22–1.90) 0.75 (0.27–1.47)
26–30 yrs old 0.92 (0.86–0.97) 1.28 (0.70–2.03) 0.85 (0.49–1.30)
31–35 yrs old 0.99 (0.91–1.07) 0.58 (0.15–1.30) 1.53 (1.02–2.15)
36–40 yrs old 1.28 (1.10–1.46) 2.05 (0.81–3.84) 1.18 (0.61–1.94)
41–45 yrs old 1.48 (1.11–1.90) 1.58 (0.15–4.54) 1.35 (0.43–2.80)
46–70 yrs old 1.02 (0.53–1.69) – 1.80 (0.34–4.40)
Father's cancer site
Head & neck 1.14 (0.95–1.34) – 0.39 (0.00–1.54)
Digestive tract 1.07 (0.98–1.17) 1.09 (0.20–2.66) 1.55 (0.61–2.91)
Thoracic 1.16 (1.03–1.30) – 1.23 (0.00–4.80)
Breast 1.09 (0.28–2.41) – –
Prostate 0.97 (0.88–1.06) – –
Reproductive 0.87 (0.67–1.10) 0.84 (0.22–1.87) 1.15 (0.59–1.90)
Skin 0.82 (0.69–0.96) 1.53 (0.48–3.16) 1.58 (0.81–2.60)
Brain & eye 0.89 (0.75–1.05) 0.25 (0.00–0.98) 0.75 (0.30–1.41)
Thyroid 1.26 (1.03–1.52) 0.63 (0.00–2.47) 1.42 (0.61–2.58)
Bone 0.88 (0.76–1.00) 2.16 (0.85–4.05) 0.82 (0.33–1.55)
Hematopoietic 0.90 (0.76–1.05) 2.01 (0.91–3.54) 1.20 (0.54–2.10)
Others 0.98 (0.88–1.09) 0.51 (0.00–2.00) 1.40 (0.56–2.64)
Father's parity status at start of observation period
Nulliparous 0.99 (0.95–1.02) 1.17 (0.62–1.90) 0.95 (0.68–1.28)
Parous 1.58 (1.20–2.03) 1.07 (0.63–1.61) 1.54 (1.06–2.10)
Father's age at diagnosis
0–12 – – 1.25 (0.33–2.78)
13–18 – – 0.95 (0.38–1.78)
19+ 0.99 (0.96–1.03) 1.11 (0.76–1.54) 1.17 (0.89–1.48)
aChildren born >1 year prior to father’s cancer diagnosis
bChildren born between 1 year before and 1 year after father’s cancer diagnosis
cChildren born >1 year after father’s cancer diagnosis
Bold number units indicate a significant difference in SMRs
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treatment and psychosocial factors. There is a direct
pathogenetic relationship between gonadal function
and some malignancies such as testicular cancer. The
adverse effects on gonadal function may also be mediated
centrally through the effects on the hypothalamo-pituitary
hormone axis. Chemotherapeutic agents, particularly al-
kylating agents (cyclophosphamide), procarbazineand
platinum-agent (cisplatin) have been identified to be
gonadotoxic [15, 16]. Radiotherapy with total-body irradi-
ation and abdomino-pelvic irradiation can also affect
reproductive function. The extent and reversibility of
these gonadal effects tend to be dose dependent and vary
by the age of the patient, type of cytotoxic regime [4, 8,
15] and the field, total dose and fractionation schedule of
radiotherapy [17–20]. However, there remains a risk of
permanent sterility.
A population based study conducted by Syse et al. in
Norway had a similar finding to our study, where male
survivors of cancer had a 24 % lower first birth rate
compared to the background population of men without
cancer of similar age, education in a similar period of
time [21]. A separate study by Green et al. evaluated the
long-term fertility of 6224 male survivors in the Child-
hood Cancer Survivor Study through questionnaires,
which showed that male survivors were 44 % less likely
to father a pregnancy than their siblings who had not
undergone cancer treatment[8].
The diagnosis of cancer can also affect the survivors
socially and psychologically to impact their attitude
towards parenthood. With increased concerns of poten-
tial disease recurrence, concerns about dying and leaving
their spouse to face single parenthood and not living
long enough to see their children grow up and fear for
the health of their offspring can impact negatively on
their desire to have children [6, 22]. Also, cancer survi-
vors are less likely to have a stable income and stable
relationship with poorer job prospects and poorer health
related quality of life; which can all affect their birth
rates [23–26].
We observed very different fertility patterns for men
with or without a child at diagnosis. Men who were
parous at diagnosis had a significantly lower birth rate
than those who were nulliparous, which is consistent
with previously reported studies of fertility in cancer
survivors [9, 21, 27]. This was reflected in all but one of
the cancer sites (Breast Cancer) in our study. This find-
ing is comparable to that in nulliparous female survivors
of cancer who had similar birth rates to the background
population in 8 out of 12 cancer sites [28]. This suggests
that the true average ‘infertility’ in men following many
types of cancers is only marginally less, if any, than the
birth rates observed in cancer-free men. This finding is
promising, as Mancini et al. showed that 33.5 % of fertile
cancer survivors aged 20–44 desired to be parents and
had the intention for additional children [29].
We identified several independent predictors of birth
following a cancer diagnosis. These included parity status
at diagnosis, cancer site, age at and time since diagnosis.
Differences in birth rates based on age at diagnosis are
likely related to the improvements in and increasing use
of fertility preservation techniques, such as sperm banking
and in-vitro fertilisation (IVF) in adolescents and adults
diagnosed with cancer; as well as the increased toxicity of
systemic treatment in children (0–12 years) and the inabil-
ity to utilise sperm-banking for pre-pubertal males. Also
men with prostate cancer are likely to be older and thus
may have completed their family and no longer desire to
have any children, which can contribute to a lower birth
rate. The independent effect on increased birth rates of
time since diagnosis may represent a physical and psycho-
logical perception of ‘cure’ from cancer, and return to
normal function, where survivors may then be more able
and willing to father a(nother) child.
Our study has also shown that offspring born to fathers
who have cancer have similar mortality rates to the back-
ground population, and are not at an increased risk of
death. This is consistent with previous studies which sug-
gest that offspring of fathers who have had cancer have
Table 7 Risk of death expressed as Mortality Rate Ratios (MRRs)
in children born to partners of men with or without a history of
cancer using a Poisson model
Group Unadj MRR (95 % CI) MRRa (95 % CI)
Background Healthy Population 1.00 1.00
Group 1 1.16 (1.11–1.20) 1.01 (0.97–1.05)
Group 2 1.05 (0.74–1.50) 1.06 (0.75–1.51)
Group 3 1.03 (0.82–1.30) 1.10 (0.87–1.38)
Father's age at childbirth
16–25 yrs old 1.00 1.00
26–30 yrs old 0.88 (0.87–0.90) 0.99 (0.96–1.01)
31–35 yrs old 0.87 (0.85–0.89) 1.05 (1.02–1.09)
36–40 yrs old 0.90 (0.87–0.93) 1.15 (1.10–1.21)
41–45 yrs old 0.95 (0.89–1.01) 1.20 (1.11–1.29)
46–70 yrs old 1.09 (0.98–1.22) 1.33 (1.18–1.50)
Mother's age at childbirth
12–20 yrs old 1.00 1.00
21–25 yrs old 0.85 (0.82–0.87) 0.94 (0.91–0.97)
26–30 yrs old 0.77 (0.75–0.79) 0.92 (0.89–0.95)
31–35 yrs old 0.80 (0.77–0.82) 0.97 (0.93–1.02)
36–40 yrs old 0.89 (0.85–0.94) 1.08 (1.02–1.15)
41–57 yrs old 1.14 (1.01–1.28) 1.34 (1.18–1.52)
unknown 5.51 (3.55–8.54) 4.96 (3.20–7.69)
aAdjusted for father’s age at childbirth, mother’s age at childbirth, father’s
socioeconomic factor, attained age of the child and calendar period. Bold
number units indicate a significant difference in MRRs
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few other complications or adverse outcomes compared
to the background population [30, 31]. This remained
constant and was not affected by the timing of birth in
relation to the cancer diagnosis. This is starkly different
from mothers with cancer, where the timing of birth plays a
major role, with offspring born around the time of diagno-
sis having a 66 % increased risk of death [32]. This is
thought to be related to the intrauterine exposure to cancer
treatment (chemotherapeutic agents and radiotherapy).
However, it is noted that offspring of parous men who
were born after diagnosis had a higher mortality rate
compared to the background population. This, coupled
with the lower birth rates in men who were parous at
diagnosis suggests that this particular group of men may
need increased support, should they desire to have fur-
ther offspring after their cancer diagnosis and treatment.
The mortality rate of offspring born around or after
the time of diagnosis was not influenced by the attained
age of the child, father’s socioeconomic status or the site
of the father’s cancer. However, increasing father’s age at
childbirth and increasing mother’s age at childbirth were
shown to be independent risk factors for increasing
mortality risk of the offspring. This is similar to the back-
ground population, where previous studies in a normal
(non-cancer) population, have demonstrated a higher
mortality rate in offspring of fathers aged 45 years or more
[33] and mothers aged 35 years or more [34–36].
With over 80,000 men who were diagnosed with can-
cer who had over 120,000 offspring in a span of 40 years,
our study is to our best knowledge, one of the largest
studies evaluating the birth rates of male cancer survi-
vors and the mortality rates of their offspring. The large
population-based design allowed for an unbiased ascer-
tainment of cancers, births and deaths. By calculating
standardized birth ratios and standardised mortality
ratios, we take into account societal changes in repro-
ductive behaviour and mortality over time.
Weaknesses of our study include the lack of informa-
tion of treatment details, which would have allowed for
a better understanding of the observed trends. There
was also absence of information on spontaneous or
induced abortions in the partner/spouse, as well as the
use of fertility preservation techniques which may have
contributed to these findings. Furthermore, the measure-
ment of fertility was implied through the birth rates of
the subject’s partner/spouse, without considering pos-
sible paternal discrepancy or misattributed paternity.
Any bias arising from this is difficult to predict as non-
paternity rates vary greatly across populations (from 0.8
to 30 %) and have been associated with different demo-
graphic factors [37]. Our study included a substantial
proportion of men who were treated decades ago and
exposed to treatment regimens that may no longer be
the standard of care. However, we observed no period
effects, suggesting that there were no major changes in
birth rates of the cancer survivors and mortality risks
among their offspring over time. The study data was not
extended beyond 2003 as more recent birth data among
cancer survivors was not available.
Conclusions
In summary, a diagnosis of cancer has an important impact
on a man’s likelihood of fathering a child after the diagnosis.
In this study, we observed the trends of changing birth rates
in male Swedish cancer survivors, which are influenced by
the site of cancer, age at and time since diagnosis. There is
also a significant difference between survivors who are
nulliparous vs. those who are parous at diagnosis, suggest-
ive of a psychological element which may over-ride the
physical ability of the survivor to have a(nother) child.
However, offspring of male cancer survivors have a similar
mortality rate to the background population, which is not
influenced by the timing of their birth in relation to the
cancer diagnosis, attained age of the child, father’s socio-
economic status or the site of the father’s cancer. Identify-
ing men at increased risk of sub-fertility or infertility
post-diagnosis, particularly those with a strong desire for
parenthood; will allow for appropriate counselling and
utilisation of fertility preservation techniques to give the
men the possibility of parenthood after a cancer diagnosis.
Abbreviations
BRR: birth rate ratios; CI: confidence interval; ICD7: International classification
of diseases, Revision 7 code; ICSI: intracytoplasmic sperm injection; IVF: in-
vitro fertilisation; MGR: multi-generation register; MRR: mortality rate ratios;
SBR: standardized birth ratios; SMR: standardized mortality ratios.
Competing interests
All authors declare that no competing interests exist.
Authors’ contributions
SWT and LJ drafted the manuscript. JL and HM participated in the study design
and performed the statistical analysis. AS, HMV and MH conceived the study
and participated in the design of the study. KC obtained the datasets and
assisted in revision of manuscript. MH coordinated the study and made
revisions to the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to acknowledge the Swedish Research Council, Swedish
Initiative for research on Microdata in the Social and Medical Sciences
(SIMSAM), grant number 80748301; National Medical Research Council,
Singapore (NMRC/1180/2008) and National University of Singapore Start-up
Fund DPRT(Grant Number R-186-000-108-133).
Financial disclosure
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Author details
1Department of Surgery, Yong Loo Lin School of Medicine, 1E Kent Ridge
Road, National University Health System, Singapore 119228, Singapore. 2Saw
Swee Hock School of Public Health, National University of Singapore, 16
Medical Drive, Singapore 117597, Singapore. 3Department of Medical
Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm,
Sweden. 4Department of Mathematics and Statistics, La Trobe University,
Bundoora, VIC 3086, Australia. 5Department of Radiology, University Medical
Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Tang et al. BMC Cancer  (2016) 16:196 Page 11 of 12
Received: 21 August 2014 Accepted: 1 March 2016
References
1. Fossa SD, Magelssen H. Fertility and reproduction after chemotherapy of
adult cancer patients: malignant lymphoma and testicular cancer.
Ann Oncol. 2004;15 Suppl 4:259–65.
2. Giwercman A, Peterson PM: Cancer and male infertility. In: Bailliere's Clinical
Endocrinology and Metabolism. edn.: Harcourt Publisher's; 2000: 453–471.
3. Meirow D, Schenker JG. Cancer and male infertility. Hum Reprod. 1995;10(8):
2017–22.
4. Wallace WH, Anderson RA, Irvine DS. “Fertility preservation for young
patients wtih cancer: who is at risk and what can be offered?lancet”.
Oncology. 2005;6(4):209–18.
5. Dohle GR. Male infertility in cancer patients: review of the literature.
Int J Urol. 2010;17:327–31.
6. Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and
experience regarding cancer infertility, and sperm banking in younger male
survivors. J Clin Oncol. 2002;20:1880–9.
7. Langeveld NE, Stam H, Grootenhuis MA, Last BF. Quality of life in young
adult survivors of childhood cancer. Support Care Cancer. 2002;10:579–600.
8. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC,
et al. Fertility of male survivors of childhood cancer: a report from the
childhood cancer survivor study. J Clin Oncol. 2010;28(2):332–9.
9. Madanat LMS, Malila N, Dyba T, Hakulinen T, Sankila R, Boice RD, et al.
Probability of parenthood after early onset cancer: a population-based
study. Int J Cancer. 2008;123(12):2891–8.
10. Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, et al.
Pregnancy outcome of partners of male survivors of childhood cancer: a report
from the childhood cancer survivor study. J Clin Oncol. 2003;21(4):716–21.
11. Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL, Mineau GP, et al.
Reproductive outcomes in male childhood cancer survivors: a linked
cancer-birth registry analysis. Arch Pediatr Adolesc Med. 2009;163(10):887–94.
12. Sweden S. Multi-generation register 2003 a description of contents and
quality Sweden: statistics. SE-701 89 Örebro, Sweden: Publication Services;
2004.
13. Mattson BWA. Completeness of the swedish cancer registry. Acta Radiol. 1984;23:
305–13.
14. World Health Organization (1957). Manual of the international statistical
classification of diseases, injuries, and causes of death: based on the
recommendations of the seventh revision Conference, 1955, and adopted
by the ninth World Health Assembly under the WHO Nomenclature
Regulations. Geneva: 1957.
15. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy
for childhood Hodgkin's disease. Med Pediatr Oncol. 1996;27(2):74–8.
16. Waring AB, Wallace WH. Subfertility following treatment for childhood
cancer. Hosp Med. 2000;61(8):550–7.
17. Castillo LA, Craft AW, Kernahan J, Evans RG, Aynsley-Green A. Gonadal
function after 12Gy testicular irradiation in childhood acute lymphoblastic
leukaemia. Med Pediatr Oncol. 1990;18(3):185–9.
18. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy.
Endocrinol Metab Clin North Am. 1998;27(4):927–43.
19. Sklar CA, Robison LL, Nesbit ME, Sather HN, Meadows AT, Ortega JA, et al.
Effects of radiation on testicular function in long-term survivors of
childhood acute lymphoblastic leukemia: a report from the children cancer
study group. J Clin Oncol. 1990;8(12):1981–7.
20. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al.
Pregnancies following high-dose cyclophosphamide with or without
high-dose busulfan or total-body irradiation and bone marrow
transplantation. Blood. 1996;87(7):3045–52.
21. Syse A, Kravdal O, Tretli S. Parenthood after cancer—a population-based
study. Psychooncology. 2007;16:920–7.
22. Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young
adult survivors of childhood cancer. Psychooncology. 2004;13(10):689–99.
23. Amir Z, Moran T, Walsh L, Iddenden R, Luker K. Return to paid work after
cancer: a British experience. J Cancer Surviv. 2007;1(2):129–36.
24. Gurney JG, Krull KR, Kadan-Lottick N, Nicholson HS, Nathan PC, Zebrack B,
et al. Social outcomes in the childchood cancer survivor study cohort.
J Clin Oncol. 2009;27(14):2390–5.
25. Blaauwbroek R, Stant AD, Groenier KH, Kamps WA, Meyboom B, Postma A.
Health-related quality of life and adverse late effects in adult (very) long-term
childhood cancer survivors. Eur J Cancer. 2007;43:122–30.
26. Greaves-Otte JGW, Greaves J, Kruyt PM, van-Leeuwen O, Van-der-Wouden
JC, Van-der-Does E. Problems at social re-integration of long-term cancer
survivors. Eur J Cancer Clin Oncol. 1991;27(2):178–81.
27. Magelssen H, Melve KK, Skjaerven R. Parenthood probability and pregnancy
outcomes in patients with a cancer diagnosis during adolescence and
young adulthood. Hum Reprod. 2008;23:178–86.
28. Hartman M, Liu J, Czene K, Miao H, Chia KS, Salim A, Verkooijen HM: Birth
rates among female cancer survivors: a population-based cohort study.
Cancer. 2013;119(10):1892-9. Epub ahead of print.
29. Mancini J, Rey D, Preau M, Corroller-Soriano AGL, Moatti J-P. Barriers to
procreational intentions among cancer survivors 2 years after diagnosis:
a french national cross-sectional survey. Psychooncology. 2011;20(1):12–8.
30. Nygaard R, Clausen N, Siimes MA, Marky I, Skjeldestad FE, Kristinsson JR,
et al. Reproduction following treatment for childhood leukemia: a population-
based propsective cohort study of fertility and offspring. Med Pediatr Oncol.
1991;19(6):459–66.
31. Fossa SD, Magelssen H, Melve K, Jacobsen AB, Langmark F, Skjaerven R.
Parenthood in survivors after adulthood cancer and perinatal health in their
offspring: a preliminary report. J Natl Cancer Inst Monogr. 2005;34:77–82.
32. Verkooijen HM, Ang JX, Liu J, Czene K, Salim A, Hartman M. Mortality
among offspring of women diagnosed wtih cancer: a population-based
cohort study. Int J Cancer. 2013;132(10):2432–8.
33. Zhu JL, Vestergaard M, Madsen KM, Olsen J. Paternal age and mortality in
children. Eur J Epidemiol. 2008;23(7):443–7.
34. Fretts RC, Schmittdiel J, McLean FH, Usher RH, Godlman MB. Increased
maternal age and the risk of fetal death. N Eng J Med. 1995;333:953–7.
35. Hansen JP. Older maternal age and pregnancy outcome: a review of the
literature. Obstet Gynecol Surv. 1986;41(11):726–42.
36. Myrskyla M, Fenelon A. Maternal age and offspring adult health: evidence
from the health and retirement study. Demography. 2012;49(4):1231–57.
37. Bellis MA, Hughes K, Hughes S, Ashton JR. Measuring paternal discrepancy
and its public health consequences. J Epidemiol Community Health. 2005;
59:749–54.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tang et al. BMC Cancer  (2016) 16:196 Page 12 of 12
